Drug intelligence / Profile preview

FURESTEM-RA

Development stage: Phase 2
Lead developer: Kangstem Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

FURESTEM-RA is an allogeneic human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) therapy developed by Kangstem Biotech for the treatment of moderate to severe rheumatoid arthritis. The therapy leverages the immunomodulatory and anti-inflammatory properties of mesenchymal stem cells to regulate the immune system's overactivity and promote tissue repair in affected joints. FURESTEM-RA has completed Phase 1 and Phase 1/2a clinical trials in South Korea, which evaluated its safety and preliminary efficacy. As of late 2023, the program received IND approval for a Phase 2b clinical trial to further evaluate its therapeutic potential in rheumatoid arthritis patients.

Brand names: FURESTEM-RAPureStem-RA
Other names: 퓨어스템-알에이주FURESTEM-RA Inj.

Beyond the preview

Go deeper on FURESTEM-RA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FURESTEM-RA.

Explore the full profile